Compare iShares International Treasury Bond ETF (IGOV) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares International Treasury Bond ETF vs Smith & Nephew plc — how do they compare? iShares International Treasury Bond ETF trades at $39.67 (market cap $1.30B), while Smith & Nephew plc trades at $27.14 (market cap $11.10B). The key difference: Smith & Nephew plc is far larger — about 8.5× iShares International Treasury Bond ETF's market cap, and Smith & Nephew plc pays a 2.95% dividend while iShares International Treasury Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares International Treasury Bond ETF for 92 Days and Smith & Nephew plc for 120 Days on average.
| IGOV | SNN | |
|---|---|---|
Market Cap | $1.30B | $11.10B |
Volume | 693,740 | 1,051,703 |
Sector | Fixed Income | Health |
52-Week High | $42.99 | $37.17 |
52-Week Low | $39.65 | $26.42 |
Typical Hold Time | 92 Days | 120 Days |
Enterprise Value | — | $14.13B |
Dividend Yield | — | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IGOV trades at $39.67, down 0.08% with a bearish technical signal from moving averages, while oscillators are neutral. Key financial ratios are unavailable, limiting fundamental clarity. Recent news highlights rising global bond yields, which may impact interest rate-sensitive stocks.
The outlook is cautious due to missing financial data and bearish technicals. Risks include macroeconomic pressure from higher yields, while opportunities depend on future earnings visibility. Investors need updated financials to assess valuation and growth prospects accurately.
SNN trades at $27.10, near its 52-week low, with a bearish technical signal. The company reported solid fundamentals with revenue growth to $6.16B in 2025 and a net income margin of 10.08%. Recent product launches, like the EVOS PELVIC System, aim to strengthen its medical technology portfolio. Cash flow from operations remains strong at $1.29B, though net cash flow was negative $64M in 2025.
The outlook is mixed: strong profitability and innovation support long-term value, but near-term headwinds include analyst downgrades and competitive pressures. Risks involve execution challenges and market sentiment. The stock presents a cautious opportunity for value investors, balancing solid fundamentals against current bearish trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares International Treasury Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index and will invest at least 90% of its assets in fixed income securities included in the underlying index. The underlying index measures the performance of fixed-rate, local currency, investment-grade, sovereign bonds from certain developed markets. The fund is non-diversified.
Read more on IGOV →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
